TD Cowen Reiterates Rating on DexCom, Inc. $DXCM
Key Points
- TD Cowen now rates DexCom, Inc. ($DXCM) "buy" with a $95.00 target.
- The Street's average $DXCM price target is $84.67 (Strong Buy).
- $DXCM last traded around $75.37.
TD Cowen reiterated its rating on DexCom, Inc. ($DXCM) to a "buy" rating, with a price target of $95.00 in a recent research note.
DexCom, Inc. ($DXCM) Stock
DexCom, Inc. Earnings
Analysts Set New Price Targets
About DexCom, Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.